Clinical Trial
Journal Article
Add like
Add dislike
Add to saved papers

[ 18 F]MFBG PET/CT outperforming [ 123 I]MIBG SPECT/CT in the evaluation of neuroblastoma.

PURPOSE: Iodine 123 labeled meta-iodobenzylguanidine ([123 I]MIBG) scan with SPECT/CT imaging is one of the most commonly used imaging modalities in the evaluation of neuroblastoma. [18 F]-meta-fluorobenzylguanidine ([18 F]MFBG) is a novel positron emission tomography (PET) tracer which was reported to have a similar biodistribution to [123 I]MIBG. However, the experience of using [18 F]MFBG PET/CT in the evaluation of patients with neuroblastoma is limited. This preliminary investigation aims to assess the efficacy of [18 F]MFBG PET/CT in the evaluation of neuroblastomas in comparison to [123 I]MIBG scans with SPECT/CT.

MATERIALS AND METHODS: In this prospective, single-center study, 40 participants (mean age 6.0 ± 3.7 years) with history of neuroblastoma were enrolled. All children underwent both [123 I]MIBG SPECT/CT and [18 F]MFBG PET/CT studies. The number of lesions and the Curie scores revealed by each imaging method were recorded.

RESULTS: Six patients had negative findings on both [123 I]MIBG and [18 F]MFBG studies. Four of the 34 patients (11.8%) were negative on [123 I]MIBG but positive on [18 F]MFBG, while 30 patients were positive on both [123 I]MIBG and [18 F]MFBG studies. In these 34 patients, [18 F]MFBG PET/CT identified 784 lesions while [123 I]MIBG SPECT/CT detected 532 lesions (p < 0.001). The Curie scores obtained from [18 F]MFBG PET/CT (11.32 ± 8.18, range 1-27) were statistically higher (p < 0.001) than those from [123 I]MIBG SPECT/CT (7.74 ± 7.52, range 0-26). 30 of 34 patients (88.2%) with active disease on imaging had higher Curie scores based on the [18 F]MFBG study than on the [123 I]MIBG imaging.

CONCLUSION: [18 F]MFBG PET/CT shows higher lesion detection rate than [123 I]MIBG SPECT/CT in the evaluation of pediatric patients with neuroblastoma.

CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov : NCT05069220 (Registered: 25 September 2021, retrospectively registered); Institute Review Board of Peking Union Medical College Hospital: ZS-2514.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app